Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes ...

Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to ...

BOSTON & BATESVILLE, Ind.--(BUSINESS WIRE)--Bain Capital, a leading private investment firm, today announced a majority investment in the Milacron Injection Molding and Extrusion business (or the ...

TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ...

Keith Largay joined Bain Capital’s real estate business as head of real estate capital markets, a spokesperson confirmed. It ...

According to the terms of the deal, Bain has agreed to acquire a 51 percent stake in Milacron for $287 million.

Independent company plans significant investment in innovation, both internal product development and external licensing and acquisitions, supported by Bain Capital investment Founded in 1678 ...

Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is acquiring Mitsubishi Tanabe Pharma Corporation in a multi-billion ...

Keith Largay joins Bain Capital from JLL, where he spent 14 years and most recently served as co-head of its Chicago office.

Following rumblings of a private equity bidding war late last year, Bain Capital has emerged triumphant on its quest to obtain Japanese drugmaker Mitsubishi Tanabe Pharma. Bain is laying out 510 ...